BRENDA WINDEMUTH: Open Payments
NPI 1629057773 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$697 in 29 payments from 14 companies in 2025. Trend: 2023 $629 · 2024 $963 · 2025 $697
Food & beverage: $697
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $107 |
| Verona Pharma, Inc. | 5 | $99 |
| GENZYME CORPORATION | 3 | $79 |
| GlaxoSmithKline, LLC. | 2 | $49 |
| Vifor Pharma, Inc. | 1 | $27 |
| United Therapeutics Corporation | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $23 |
Products named: DUPIXENT, GLASSIA, Ohtuvayre, NUCALA, Zemaira, Tyvaso, OPSYNVI, TERLIVAZ.
Industry payments across MD — which companies pay providers there.
